Ann: ATL1102 DMD Clinical Trial Application Submitted in Europe, page-64

I personally have no idea why some give Akki such a hard time just because his/her views are contrary to your own. In fact Akki has been correct about a number of things over the years and has never beat his/her chest over it. I use Akki's comments as a way to challenge my own thoughts on the company.

I still remember Akki correctly pointed out during Serepta's CR that their comments regarding partnerships and acquisitions was a generic paragraph they always include in all their previous CRs but received backlash over it. Unpopular opinion but Akki is one of the few posters I actually pay attention to. At least he/she doesn't flood their comments with $ $ $ $ symbols and post outrageous share price predictions.